Forma Gets $20M Deal with Eisai
Cambridge, MA-based Forma Therapeutics has struck a collaboration deal with the U.S. unit of Tokyo-based drug powerhouse Eisai that is focused on discovering drugs against normally intractable disease targets, according to the companies. Eisai is paying Forma $20 million in upfront and committed fees over a three-year period, according to the companies. The deal gives Eisai non-exclusive access to Forma’s proprietary compound library and cell-based screening platforms to aid in Eisai’s discovery of new drugs for its own pipeline. Forma is eligible for potential milestone payments and royalties on products that Eisai might decide to develop as a result of the collaboration.